Baylor College of Medicine Cancer Center

描述（由申请人提供）：这是Dan L.的第一次CCSG竞争性更新。休斯顿贝勒医学院邓肯癌症中心（DLDCC）。休斯顿位于德克萨斯州医疗中心（TMC），这是全国最大的医疗中心，休斯顿是人口非常多样化的第四大城市。DLDCC是一个矩阵癌症中心，与三个医院附属机构，得克萨斯州儿童，DeBakey退伍军人事务医疗中心和Ben Taub综合医院作为正式的临床合作伙伴，作为主要的科学合作伙伴。该中心成立于2002年，并于2007年7月获得NCI认证，此后在加强其科学研究计划方面取得了重大进展，同时考虑到我们EAB的事先审查和建议。37个新的癌症教师已被招募到DLDCC，现在有350名正式成员，我们的癌症相关的同行评审研究资金现在超过1.22亿美元（增长22%），其中超过3600万美元来自NCI。成员们已经取得了几项具有高度影响力的研究成果，其中几项有可能降低癌症死亡率。DLDCC包括7个研究项目：癌症生物学，病毒和分子肿瘤发生，核受体，乳腺癌，癌细胞和基因治疗，癌症预防和人口科学，以及儿科癌症。超过1 000万美元的投资加强了科学资源，为成员提供了领先的技术和专门知识。CTSU得到了显著加强，临床试验的应计费用增加了40%以上。少数种族和族裔的应计费用仍然没有着落。外展和健康差距办公室利用国家癌症研究所资助开发的工具，向社区，特别是服务不足的社区传播新的信息。在这次更新中，我们要求为我们的10个共享资源、3个开发资源和其他对我们的使命和目标很重要的活动增加资金，并考虑根据NCI指导方针进行全面指定。

DESCRIPTION (provided by applicant): This is the 1st CCSG competitive renewal of the Dan L. Duncan Cancer Center (DLDCC) at Baylor College of Medicine (BCM) in Houston. BCM is located in the Texas Medical Center (TMC), the largest medical center in the country, and Houston is the 4th largest city with a very diverse population. The DLDCC is a matrix Cancer Center with BCM as the lead scientific partner with three hospital affiliates, Texas Children's, the DeBakey Veterans Affairs Medical Center, and Ben Taub General Hospital, as formal clinical partners. The Center was established in 2002 and received NCI designation in July of 2007 and has since made significant progress strengthening its scientific research programs, taking into consideration the prior review and recommendations from our EAB. 37 new cancer faculty have been recruited to the DLDCC which now has 350 formal members, and our cancer-relevant peer reviewed research funding now exceeds $122 million (22% increase), with more than $36 million coming from the NCI. Several high-impact research accomplishments have been made by members, several with the potential to reduce cancer mortality. The DLDCC comprises 7 research programs: Cancer Biology, Viral and Molecular Oncogenesis, Nuclear Receptors, Breast Cancer, Cancer Cell and Gene Therapy, Cancer Prevention and Population Science, and Pediatric Cancer. Investments exceeding $10 million have strengthened the scientific resources, which offer leading technologies and expertise to members. CTSU has been significantly enhanced and accruals to clinical trials have increased over 40%. Accrual of racial and ethnic minorities continues to be outstanding. The Office of Outreach and Health Disparities, using tools developed from NCI funding, disseminates new information to the community, especially the underserved. In this renewal, we ask for increased funding for our 10 Shared Resources, 3 developing resources, and other activities important to our mission and goals, as well as consideration for comprehensive designation according to NCI guidelines.